Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Bio-Techne (TECH) Long-Term Deferred Tax (2025)

Bio-Techne has reported Long-Term Deferred Tax over the past 3 years, most recently at $10.3 million for Q2 2025.

Quarterly results put Long-Term Deferred Tax at $10.3 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Jun 2025 was $10.3 million (changed N/A YoY), and the annual figure for FY2025 was $10.3 million, changed.
Long-Term Deferred Tax for Q2 2025 was $10.3 million at Bio-Techne, up from $539000.0 in the prior quarter.
Over the last five years, Long-Term Deferred Tax for TECH hit a ceiling of $10.3 million in Q2 2025 and a floor of $10.3 million in Q2 2025.